ATE211387T1 - Oral 1alpha-hydroxyprevitamin d - Google Patents

Oral 1alpha-hydroxyprevitamin d

Info

Publication number
ATE211387T1
ATE211387T1 AT93916684T AT93916684T ATE211387T1 AT E211387 T1 ATE211387 T1 AT E211387T1 AT 93916684 T AT93916684 T AT 93916684T AT 93916684 T AT93916684 T AT 93916684T AT E211387 T1 ATE211387 T1 AT E211387T1
Authority
AT
Austria
Prior art keywords
hydroxyprevitamin
vitamin
oral
1alpha
alpha
Prior art date
Application number
AT93916684T
Other languages
English (en)
Inventor
Joyce C Knutson
Charles R Valliere
Charles W Bishop
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Application granted granted Critical
Publication of ATE211387T1 publication Critical patent/ATE211387T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT93916684T 1992-06-22 1993-06-22 Oral 1alpha-hydroxyprevitamin d ATE211387T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90188692A 1992-06-22 1992-06-22
PCT/US1993/005961 WO1994000128A1 (en) 1992-06-22 1993-06-22 ORAL 1α-HYDROXYPREVITAMIN D

Publications (1)

Publication Number Publication Date
ATE211387T1 true ATE211387T1 (de) 2002-01-15

Family

ID=25414989

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93916684T ATE211387T1 (de) 1992-06-22 1993-06-22 Oral 1alpha-hydroxyprevitamin d

Country Status (11)

Country Link
US (6) US5622941A (de)
EP (1) EP0600079B1 (de)
JP (1) JP3722832B2 (de)
AT (1) ATE211387T1 (de)
AU (2) AU4645893A (de)
CA (1) CA2116238C (de)
DE (1) DE69331409T2 (de)
DK (1) DK0600079T3 (de)
ES (1) ES2170069T3 (de)
NZ (1) NZ254424A (de)
WO (1) WO1994000128A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5493027A (en) * 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US5696103A (en) * 1995-11-17 1997-12-09 Syntex (U.S.A.) Inc. Method for treating osteoporosis
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
CA2279590A1 (en) * 1997-02-13 1998-08-20 Bone Care International, Inc. Targeted therapeutic delivery of vitamin d compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AU762481C (en) 1998-03-27 2004-08-19 Oregon Health Sciences University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
US6051567A (en) * 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
CA2414407A1 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. Stabilized 1.alpha.-hydroxy vitamin d
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
EA008072B1 (ru) * 2001-12-03 2007-02-27 Новацея, Инк. Фармацевтические составы, содержащие соединения активного витамина d
US20050026871A1 (en) * 2002-07-17 2005-02-03 Moshe Flashner-Barak Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
US7566696B2 (en) * 2002-09-05 2009-07-28 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20040162292A1 (en) * 2002-12-03 2004-08-19 Evenstad Kenneth L. Multivitamin formulations for promoting healthy collagen, and methods of their use
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
AU2004296877A1 (en) * 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
WO2006088765A1 (en) * 2005-02-14 2006-08-24 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
EP1945185B1 (de) * 2005-10-12 2016-02-03 Proventiv Therapeutics, LLC Verfahren und artikel zur behandlung von 25-hydroxyvitamin-d-insuffizienz und mangel
DK3095447T3 (da) * 2006-02-03 2022-01-31 Opko Renal Llc Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
PL2481400T3 (pl) * 2007-04-25 2015-04-30 Opko Ip Holdings Ii Inc Sposoby i kompozycje dawki doustnej do kontrolowanego uwalniania związku będącego witaminą D
WO2008134518A2 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
EP3225243A1 (de) 2007-04-25 2017-10-04 Opko Renal, LLC Verfahren zur sicheren und effektiven behandlung und vorbeugung von sekundärem hyperparathyroidismus für chronische nierenerkrankung
ES2954932T3 (es) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados
CN105796530A (zh) 2010-03-29 2016-07-27 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
US9416102B2 (en) * 2013-01-23 2016-08-16 Wisconsin Alumni Research Foundation (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3193925A2 (de) 2014-08-07 2017-07-26 OPKO Ireland Global Holdings, Ltd. Adjunktive therapie mit 25-hydroxyvitamin d
MX2018011820A (es) 2016-03-28 2019-01-24 Opko Ireland Global Holdings Ltd Metodos de tratamiento con vitamina d.
EP3843706A1 (de) * 2018-08-31 2021-07-07 OPKO Ireland Global Holdings, Ltd. Pädiatrische darreichungsformen von vitamin d, verfahren zu deren herstellung und verwendung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2216719A (en) * 1935-07-06 1940-10-08 Hartford Nat Bank & Trust Co Vitamin
US2434015A (en) * 1942-11-21 1948-01-06 Du Pont Stable provitamin d composition
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
DE3270978D1 (en) * 1981-07-17 1986-06-12 Duphar Int Res Method of preparing 1-alpha-hydroxyvitamin d and 1-alpha-hydroxy-previtamin d compounds, and adduct of a previtamin d or tachysterol compound with a suitable dienophile
JPS5910562A (ja) * 1982-07-07 1984-01-20 Teijin Ltd プレ−１α−ヒドロキシコレカルシフエロ−ル類の製造法
DE3490215C2 (de) * 1983-05-09 1991-07-25 Wisconsin Alumni Res Found
US4505906A (en) * 1984-01-30 1985-03-19 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 isomers
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
JPS6218A (ja) * 1985-03-14 1987-01-06 Chugai Pharmaceut Co Ltd 皮膚疾患治療用組成物
JPS649932A (en) * 1987-07-01 1989-01-13 Toyo Capsel Kk Soft capsule preparation using newly combined component as the base
ZA886284B (en) * 1987-08-31 1990-04-25 Advanced Polymer Systems Inc Controlled release formulations
AU5185790A (en) * 1989-02-16 1990-09-05 University Of Georgia Research Foundation, Inc., The Treatment of tibial dyschondroplasia
US5013728A (en) * 1990-05-04 1991-05-07 Colgate - Palmolive Company Composition for treating osteoporosis and hormonal imbalance
EP0503035B1 (de) * 1990-09-21 2001-12-12 Bone Care International, Inc. Neues 1alpha-hydroxy vitamin-d4 und neue zwischenprodukte und analoge
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物

Also Published As

Publication number Publication date
DK0600079T3 (da) 2002-04-15
NZ254424A (en) 1997-09-22
DE69331409T2 (de) 2002-08-29
AU4645893A (en) 1994-01-24
JP3722832B2 (ja) 2005-11-30
US6150346A (en) 2000-11-21
EP0600079B1 (de) 2002-01-02
DE69331409D1 (de) 2002-02-07
JPH07501343A (ja) 1995-02-09
US6147064A (en) 2000-11-14
AU696402B2 (en) 1998-09-10
EP0600079A1 (de) 1994-06-08
US5529991A (en) 1996-06-25
CA2116238C (en) 2007-09-04
CA2116238A1 (en) 1994-01-06
US5622941A (en) 1997-04-22
ES2170069T3 (es) 2002-08-01
US5614513A (en) 1997-03-25
AU6060896A (en) 1996-10-03
WO1994000128A1 (en) 1994-01-06
US6133250A (en) 2000-10-17

Similar Documents

Publication Publication Date Title
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
WO1994027589A3 (en) Antidepressant dosage form
NO306457B1 (no) 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament
DE1001772T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
NO920740D0 (no) Doseringsform for oral administrering av hypoglykemisk glipizid
NO306377B1 (no) Doseform for avgivelse av et medikament
GR1000465B (el) Μεθοδος παρασκευης φαρμακευτικων συνθεσεων που περιεχουν ακετυλ d-καρνιτινη για την θεραπευτικη αγωγη του γλαυκωματος.
IT1270594B (it) Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
DE69628163D1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
IT1235153B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
KR970025615A (ko) 암 전이 억제제
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
EP0438147A3 (en) Pharmaceutical compositions and dosage forms for the oral administration of calcitonin
AR002946A1 (es) Un conjunto para uso en el tratamiento o la prevencion de la osteoporosis en los mamiferos de acuerdo con una dieta ciclica.
HUT73500A (en) Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf
ATE329577T1 (de) Bismut enthaltende arzneimittel in topischen darreichungsformen
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця
CO4180553A1 (es) Composiciones para el tratamiento de la peridontitis adulta
ITMI931104A1 (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee